In 2015, the U.S. Food and Drug Administration (FDA) made history by approving Flibanserin, the first treatment for female sexual dysfunction, specifically addressing hypoactive sexual desire disorder (HSDD) in premenopausal women. Marketed under the brand name Addyi. This medication provides an option for women experiencing distress due to low sexual...